Ceftazidime-Avibactam plus Aztreonam for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria
Abiu Sempere, Belén Viñado, Ibai Los‐Arcos, David Campany, Nieves Larrosa, Nuria Fernández‐Hidalgo, Dolors Rodríguez-Pardo, Juan José González‐López, Xavier Nuvials, Benito Almirante, Laura Escolà‐Vergé
Abstract
This is a retrospective single-center study of 24 patients who received ceftazidime-avibactam plus aztreonam (CZA/ATM) for the treatment of VIM-type-producing Gram-negative bacillus (GNB) infections. The bacteria isolated were Enterobacterales in 22 patients and Pseudomonas aeruginosa in 2. Sixteen out of 19 isolates showed synergistic activity. Two patients presented clinical failure at day 14, and the 30-day mortality was 17% (4/24).
Topics & Concepts
Ceftazidime/avibactamAztreonamCeftazidimePseudomonas aeruginosaMicrobiologyMedicineEnterobacteriaceaeBacteriaBiologyEscherichia coliGeneticsBiochemistryGeneAntibiotic Resistance in BacteriaVibrio bacteria research studiesAntibiotics Pharmacokinetics and Efficacy